STOCK TITAN

Journey Medical Corporation to Participate in the 36th Annual ROTH Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Journey Medical Corporation (DERM) will participate in the 36th Annual ROTH Conference, with the President and CEO engaging in a fireside chat and one-on-one meetings. A webcast of the chat will be accessible on the company's website.
Positive
  • None.
Negative
  • None.

SCOTTSDALE, Ariz., March 13, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that management will participate in the 36th Annual ROTH Conference, which is being held March 17-19, 2024 in Dana Point, California.

Claude Maraoui, President and Chief Executive Officer, will participate in a fireside chat on Monday, March 18 at 9:30 a.m. PT and will be available for one-on-one meetings throughout the conference.

A webcast of the company’s fireside chat will be available on the News and Events page of the Investors section of Journey Medical’s website, www.journeymedicalcorp.com, for approximately 30 days after the meeting.

About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The company currently markets seven branded and two generic products that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.

Company Contact:
Jaclyn Jaffe
Journey Medical Corporation
(781) 652-4500
ir@jmcderm.com

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com


The conference is scheduled for March 17-19, 2024.

Claude Maraoui, the President and CEO of Journey Medical Corporation.

The webcast will be available on the News and Events page of Journey Medical's website.
Fortress Biotech Inc

NASDAQ:FBIO

FBIO Rankings

FBIO Latest News

FBIO Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
US
New York

About FBIO

fortress biotech, inc. is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. fortress plans to develop and commercialize products that it acquires both directly as well as indirectly by establishing subsidiary companies, also known as fortress companies. the company will leverage its biopharmaceutical business expertise and drug development capabilities to help the fortress companies achieve their goals. additionally, the company will provide funding and management services to each of the fortress companies and from time to time the company and the fortress companies will seek licensing, partnerships, joint ventures, and/or public and private financings to accelerate and provide additional funding to support their research and development programs.